|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating Costs and Expenses: | |||||
| General and administrative | |||||
| Research and development | |||||
| In-process research and development impairment | |||||
| Goodwill impairment | |||||
| Total Operating Costs and Expenses | |||||
| Loss from Operations | |||||
| Other Income: | |||||
| Foreign currency exchange gain (loss) | |||||
| Interest income | |||||
| Total Other Income | |||||
| Net Loss before income taxes | |||||
| Income tax benefit | |||||
| Effect of Warrant exercise price adjustment | |||||
| Net Loss | |||||
| Gain (loss) on foreign currency translation | |||||
| Total comprehensive loss | |||||
| Less deemed dividend from warrant inducement | |||||
| Net Loss Attributable to Common Stockholders | |||||
| Net Loss Per Share - Basic (in dollars per share) | |||||
| Net Loss Per Share - Dilutive (in dollars per share) | |||||
| Weighted average number of shares outstanding during the period - Basic (in shares) | |||||
| Weighted average number of shares outstanding during the period - Dilutive (in shares) | |||||
Loading...